In 2019, Louisiana launched a groundbreaking public health initiative to eliminate Hepatitis C by securing a fixed-cost agreement for unlimited access to life-saving DAA medication. Targeting Medicaid recipients and incarcerated populations, the program rapidly scaled testing and treatment, curing over 30,000 people and reducing mortality by 13%. With national attention and measurable cost savings, the program is now considered a model for tackling high-cost diseases across the U.S.